NHS Framework for the NHS London Region, Branded Medicines - Tranche A

Description

NHS Framework for the NHS London Region, Branded Medicines - Tranche A, Annual Tranche - Cytokine Modulators and other products, and Dolutegravir / Lamivudine Offer reference number: CM/PHR/16/5516 CM/PHR/16/5516/01 - London Tranche A - 1 September 2020 to 31 August 2022 with an option to extend (at the Authority's discretion) for a period or periods up to a total of 24 months CM/PHR/16/5516/02 - London Annual Tranche - Cytokine Modulators and other products - 1 September 2020 to 31 August 2021 with an option to extend (at the Authority's discretion) for a period or periods up to a total of 12 months CM/PHR/16/5516/03 - NHS Framework agreement for the supply of Dolutegravir / Lamivudine - North of England - 1 September 2020 - 28 February 2021, South of England - 1 September 2020 - 31 August 2021, Midlands & East - 1 September 2020 - 28 February 2022, all with an option to extend (at the Authority's discretion) for a period or periods up to a total of 24 months

Related Contracts